A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

Exclusion Criteria

• •Have significant history of, or current, cardiovascular (CV), respiratory, hepatic (hepatic applies to Group 1 only), renal, gastrointestinal, endocrine, hematological, or neurological disorders
• •Have severe atopy or a history of clinically significant multiple or severe drug allergies
• •Have known allergies to lepodisiran, related compounds, or any components of the formulation
• •Have a history of, or current, psychiatric disorders
• •Have had any malignancy within the past 5 years
• •Have estimated glomerular filtration rate (eGFR) less than 60 milliliters per minute per 1.73 m² (mL/min/1.73 m²) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
• •Have participated, within the last 1 month, in a clinical study involving an investigational product